Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Fulcrum Therapeutics, Inc.

NASDAQ: FULC · Life Sciences · 2 alerts · CIK 1680581

Share price
$3.71Close, Nov 16
Market cap
$283M
Shares outstanding
76.38MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Fulcrum Therapeutics, Inc. filings on SEC EDGAR ↗

4:17 PM ET 10-Q
Financial Results

Fulcrum Therapeutics Q3 2026 Results: Net Loss of $10.9M, Loss Narrows

Fulcrum Therapeutics is currently pursuing a merger with Slate Medicines, Inc. while undergoing significant restructuring, including the cessation of clinical development for pociredir and a workforce reduction. The company reported a net loss of $56.0 million for the nine months ended September 30, 2026, and currently has no product candidates in active clinical development.

Key figure
Net loss $10.9M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.